Efficacy of Gefitinib Combined with Pemetrexed and Cisplatin in the Treatment of Advanced Lung Adenocarcinoma
Objective To analyze the efficacy of gefitinib combined with pemetrexed and cisplatin in the treatment of advanced lung adenocarcinoma.Methods 62 patients with advanced lung adenocarcinoma admitted to Wuxi Second People's Hospital from May 2018 to May 2023 were selected as the research objects,and they were divided into che-motherapy group and targeted group by dice,31 cases in each group.The chemotherapy group was treated with peme-trexed plus cisplatin,and the targeted group added with gefitinib therapy based on the chemotherapy group.Clinical remission rate and total incidence of adverse reactions were compared.Results The remission rate reached 64.52%in the targeted group,higher than 35.48%in the chemotherapy group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in total incidence of adverse reactions between 19.35%in the targeted group and 9.68%in the chemotherapy group(χ2=1.169,P>0.05).Conclusion Gefitinib combined with peme-trexed plus cisplatin has a good effect,can improve the remission rate,and does not increase the adverse reactions dur-ing the visit,and is more suitable for patients with advanced lung adenocarcinoma.
NETL
NSTL
万方数据
